Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie's ex-Humira growth products showed solid growth in Q3, boosting management's confidence in their success. The company upgraded its guidance, raised its full-year revenue estimates, and adjusted its EPS outlook. AbbVie stock has been impacted by industry rotation and macroeconomic headwinds, but its profitability grade supports confidence in a subsequent recovery.

AbbVie: Get Ready For More Painful Downside

Apple

AMC Entertainment

Amazon

Salesforce

Altamira Therapeutics Ltd

Disney

GameStop

Unlimited HFND Multi-Strategy Return Tracker ETF

Microsoft

Nutanix

NVIDIA

Pure Storage

RedHill Biopharma

Snowflake

Tesla

Ulta Beauty

Stocks are poised for an upbeat finish to the best month of gains for 2023, as the fever pitch around Fed rate cuts next year grows. It's all teeing up nicely for that Santa rally, maybe.

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share.

AbbVie to Acquire ImmunoGen in $10 Billion Deal

AbbVie has consistently been one of the best-performing Dividend Kings over the past 10 years. With its flagship drug in decline, however, the company's shares have faltered in 2023.

AbbVie Should Consider a Dividend Cut -- Here's Why

AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market for cancer treatments.

AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio

AbbVie Inc. ABBV, +0.30% announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN, +0.50% in a cash deal valued at $10.1 billion. Under terms of the agreement, AbbVie will pay $31.26 in cash for each ImmunoGen share outstanding, which represents a 94.6% premium to Wednesday's closing price of $16.06.

AbbVie $10.1 billion deal to buy ImmunoGen values the stock at a 95% premium

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations ImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignancies Transaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billion AbbVie to hold an investor conference call at 8:00 a.m. CT NORTH CHICAGO, Ill.

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

A proven track record of putting shareholders first is part of the litmus test that I use before buying stocks. AbbVie's recent 4.7% dividend hike builds on an impressive dividend growth streak that it inherited from its former parent company, Abbott Labs. The pharmaceutical titan held up well in the third quarter, posting a double beat.

AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)

American Express

Fiverr

Blue chip stocks are generally a strong investment for any stage of the economic cycle and tend to take advantage of overarching trends. That remains as true today as it was yesterday and will be tomorrow.

Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today's Economy

Agilent Technologies

Accenture Plc

Automatic Data Processing

Amgen

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

Booz Allen Hamilton Hld

Brookfield Renewable Partners

SPDR Bloomberg 1-3 Month T-Bill ETF

Brookfield Infrastructure

Broadridge Financial

British American Tobacco

Blackstone Group

Carrier Global

Comcast

CME Group

Cummins

Canadian National Railway Company

I've made significant changes to my portfolio due to buying a new house and selling stocks from my portfolio to raise cash. My goal is to prioritize building a passive income stream, but I recognize the value of investing in a new home for improved quality of life. In this article, I discuss different options to pay for the new home, including taking out a mortgage or selling more stock if mortgage rates remain high.

Why I Made Big Changes To My Dividend Growth Portfolio

Johnson & Johnson

Eli Lilly

Pfizer

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

4 Large Drug Stocks to Watch as IBD Market Gains Traction

Value stocks have underperformed since 2006. However, I expect a shift in market dynamics, particularly for healthcare stocks. AbbVie is a compelling value play with a 4.5% yield, strong performance, and a 4.7% dividend increase. The company is in a great position to boost long-term growth thanks to a strong portfolio and pipeline, potentially leading to lasting stock price outperformance.

4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024

Alphabet

AT&T

T-Mobile US

Verizon

With 2023 drawing to a close, it's time to start looking at 2024 and what it may bring to investors. The number one item on the list is uncertainty.

These are the top sectors for blue chip growth in 2024

LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression Data from the study will be presented at a future medical meeting and we will discuss with global health authorities the potential to support an accelerated approval NORTH CHICAGO, Ill. , Nov. 29, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).

AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.

AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag

Archer-Daniels-Midland Company

Black Hills

Emerson Electric

Federal Realty Investment Trust

Gorman-Rupp

Hormel Foods

Leggett & Platt

Altria

National Fuel Gas

Northwest Natural Gas

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years." - Dogs of the Dow. The 49 Dividend Kings screened as of November 22 represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gains ranged 18.52%-38.49% topped by Northwest Natural and Gorman-Rupp. By yield, Altria tops all. Top-ten Kingly December yields reported for NFG, ABBV, FRT, BKH, NWN, UVV, CDUAF, MMM, LEG, & MO averaged 5.86%.

Buy 6 December Dividend Kings, 4 More On Watch

News for AbbVie Stock (ABBV)